KALY has previously announced hemp extraction contracts worth a potential $15 million in revenue.
DALLAS, Texas, Aug. 30, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced its 3rd contract to extract CBD from a hemp harvest utilizing KALY’s U.S. Patented Cannabis Extraction Process.
KALY has previously announced hemp extraction contracts worth a potential $15 million in revenue. The contract today moves KALY closer to its $20 million in revenue target for its new hemp extraction line of business.
KALY ANALYST COVERAGE SPECULATING $0.05 PPS
KALY is primarily in the business of biopharmaceutical developments from its cannabis extracts derived from the company’s U.S. Patented Cannabis Extraction Process. The company recently announced a new analyst report from Goldman Small Cap Research covering new biopharmaceutical cannabis extract business development updates. The report can be found in its entirety on Goldman’s website www.goldmanresearch.com. The report speculates a potential KALY price per share of $0.05.
To view the full report visit: https://www.goldmanresearch.com/201908131248/Opportunity-Research/next-gen-edtech-firm-on-a-roll.html
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.